2024-11-02 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**1. Performance vs. S&P 500 (VOO)**

Abbott Laboratories (ABT) has underperformed the S&P 500 (VOO) with a cumulative return of 102.98% compared to the VOO's 131.38%, resulting in a negative divergence of -28.4%. This places ABT in the 13.96th percentile of its historical performance range against the VOO.

**2. Recent Price Movement**

* **Last Market:** 119.19
* **Closing Price:** 113.37
* **5-Day Moving Average:** 113.9
* **20-Day Moving Average:** 115.64
* **60-Day Moving Average:** 114.0

ABT is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating a potential downward trend. The recent jump in Last Market price to 119.19 suggests a potential rebound or short-term upward momentum. 

**3. Technical Indicators**

* **RSI:** 41.17
* **PPO:** -0.42
* **Delta_Previous_Relative_Divergence:** +1.29 (20-day) - Short-term upward trend.
* **Expected_Return:** 0.0% - Expected to generate zero percent return over the next two years compared to S&P 500.

The RSI suggests the stock is in a neutral zone, while the PPO indicates potential bearish momentum. The positive Delta_Previous_Relative_Divergence suggests short-term upward momentum. The expected return of 0% indicates that ABT is not expected to outperform the S&P 500 over the next two years.

**4. Recent Earnings and Outlook**

| Date         | EPS  | Revenue        |
|--------------|------|----------------|
| 2024-10-31  | 0.94 | $10.63 B       |
| 2024-07-31  | 0.74 | $10.38 B       |
| 2024-05-02  | 0.7  | $9.96 B        |
| 2023-11-01  | 0.82 | $10.14 B       |
| 2024-10-31  | 0.82 | $10.14 B       |

ABT's recent earnings have shown steady growth, with the most recent quarter exceeding analyst estimates. Revenue has also consistently increased, indicating positive business performance.

**5. Financial Information**

**1) Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2024-06-30 | $10.38B  | 55.64%       |
| 2024-03-31 | $9.96B   | 55.21%       |
| 2023-12-31 | $10.24B  | 55.51%       |
| 2023-09-30 | $10.14B  | 54.60%       |
| 2023-06-30 | $9.98B   | 55.07%       |

ABT shows consistent strong profitability, reflected in high profit margins across recent quarters. Revenue growth also remains positive, suggesting a healthy financial standing.

**2) Capital and Profitability:**

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2024-06-30 | $39.32B  | 3.31%     |
| 2024-03-31 | $38.81B  | 3.16%     |
| 2023-12-31 | $38.60B  | 4.13%     |
| 2023-09-30 | $37.48B  | 3.83%     |
| 2023-06-30 | $37.17B  | 3.70%     |

ABT has demonstrated a steady increase in Equity over the past year, while its ROE has remained relatively stable. These metrics indicate a robust financial position and good capital management.

**6. News and Recent Issues**

* **Recent Earnings:** Recent earnings releases have been positive, exceeding analyst expectations and showcasing strong revenue growth. 
* **Recent Market Outlook:** The market outlook for ABT is generally positive, with analysts highlighting its strong financial position, consistent profitability, and the potential for continued growth in its core businesses. 
* **Analyst Opinions:** Most analysts maintain "Hold" or "Buy" ratings on ABT, citing its strong fundamentals and growth potential. 
* **Performance Highlights:** Recent highlights include the company's continued expansion in the medical device and diagnostics markets. 

**7. Overall Analysis**

ABT is a large-cap healthcare company with a strong financial position and consistent profitability. Its recent earnings have been positive, and the company has demonstrated steady growth across its various business segments. However, ABT's current performance has lagged behind the S&P 500, and the expected return suggests it may not outperform the market in the near term. While the company has a solid track record, investors should carefully consider the potential for underperformance and the potential impact of macroeconomic factors on the healthcare industry. 
